Company intelligence / Profile preview
NexImmune, Inc.
Gaithersburg, Maryland, United Statesneximmune.com ↗
- Ownership
- Public · NEXI
- Employees
- ~6
- Development stage
- Phase 1
01
Overview
NexImmune is developing T cell immunotherapies with NEXI-001 in Phase 1/2 trials for acute myeloid leukemia and NEXI-002 for multiple myeloma. The company uses its proprietary AIM nanoparticle technology to direct specific T cell-mediated immune responses.
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- T cell immunotherapiesCell therapy
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Financials
- Market cap
- $139
- Total revenue
- $0
- Enterprise value
- $-2.4M
Beyond the preview
Go deeper on NexImmune, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NexImmune, Inc..